{"doi":"10.1128/aac.01297-22","title":"High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus","abstract":"= 4) had clearance similar to those of intermediate acetylators and much slower than typically reported, but the small sample size was limiting. The absorption rate was lower than usual, likely due to the coadministration with food, and it was faster among individuals with a low body weight. Low-body weight participants were also observed to have greater oral bioavailability. The isoniazid exposures were consistent with, or greater than, the previously reported \"elevated\" concentrations among individuals receiving 3HP and dolutegravir. The concentrations were substantially greater than those presented in previous reports among individuals receiving 3HP or isoniazid without rifapentine or dolutegravir. We discuss the implications of these findings and the possibility of a drug-drug interaction that is mediated by cellular transport. (This study has been registered at ClinicalTrials.gov under identifier NCT03435146 and has South African National Clinical Trial Registration no. DOH-27-1217-5770.).","journal":"Antimicrobial Agents and Chemotherapy","year":2023,"id":380493,"datarank":0.2685918332901633,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.027176146425048196,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.027176146425048196,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":3,"citers_with_citation_signal":1,"citers_with_endowment":1,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9581,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03435146"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":428986,"name":"Yuri F. van der Heijden","orcid":"0000-0001-7631-9796","position":1,"is_corresponding":false},{"id":656638,"name":"Matthew S. Shotwell","orcid":"0000-0002-1480-0637","position":2,"is_corresponding":false},{"id":694278,"name":"Violet Chihota","orcid":"0000-0003-1444-9266","position":3,"is_corresponding":false},{"id":279020,"name":"Mark A. Marzinke","orcid":"0000-0003-1670-8786","position":4,"is_corresponding":false},{"id":346887,"name":"Richard E. Chaisson","orcid":"0000-0003-4710-925X","position":5,"is_corresponding":false},{"id":346876,"name":"Kelly E. Dooley","orcid":"0000-0001-9013-5256","position":6,"is_corresponding":false},{"id":432140,"name":"Gavin Churchyard","orcid":"0000-0002-4269-3699","position":7,"is_corresponding":false},{"id":1145886,"name":"Ryan T. Jarrett","orcid":"0000-0002-5822-351X","position":0,"is_corresponding":true}],"reference_count":39,"raw_metadata":null,"created_at":"2026-07-19T01:17:04.905707Z","pmid":"36622148","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}